

Bibliography

Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. *Hum Mol Genet* 1999; 8: 567-74.

Adams SG, Lang AE. Can the Lombard effect be used to improve low voice intensity in Parkinson's Disease? *Eur J Disord Commun* 1992; 27: 121-7.

Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's Disease. *Neurology* 1997; 49: 393-9.

Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's Disease: A consensus meeting. *Mov Disord* 1999; 14: 911-13.

Agid Y, Ruberg M, Javoy-Agid F, et al. Are dopaminergic neurons selectively vulnerable to Parkinson's Disease? *Adv Neurol* 1993; 60: 148-64.

Ahlskog JE, Wright KF, Muentner MD, et al. Adjunctive cabergoline therapy of Parkinson's Disease: Comparison with placebo and assessment of dose responses and duration of effect. *Clin Neuropharmacol* 1996; 19: 202-12.

Alarcon F. Does combined levodopa and bromocriptine therapy in Parkinson's Disease prevent late motor complications? *Eur J Neurol* 1998; 5: 255-63.

Allain H, Destee A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's Disease. *Eur Neurol* 2000; 44: 22-30.

Antonini A, Leenders KL, Meier D, et al. T2 relaxation time in patients with Parkinson's Disease. *Neurology* 1993; 43: 697-700.

Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's Disease affects neither memory nor executive functions: A consecutive series of 62 patients. *Ann Neurol* 1999; 46: 217-23.

Arle JE, Alterman RL. Surgical options in Parkinson's Disease. *Med Clin North Am* 1999; 83: 483-98.

Arnold G, Bondy B, Bandmann O, et al. 3H-spiperone binding to lymphocytes fails in the

differential diagnosis of de novo Parkinson syncromes. *J Neral Transm* 1993; 5: 107-16.

Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. *Lancet* 1998; 352: 1478.

Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. *J Neurol Neurosurg Psychiatry* 1997; 63: 421-8.

Backlund EO, Granberg PO, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism: First clinical trials. *J Neurosurg* 1985; 62: 169-73.

Bakay RA, Watts RL, Freeman A, et al. Preliminary report on adrenal-brain transplantation for parkinsonism in man. *Stereotact Funct Neurosurg* 1990; 54-55: 312-23.

Bakheit AM, Henderson LM, Moore AP, et al. Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's Disease. Interim results. *Eur Neurol* 1990; 30: 108-11.

Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson's Disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. *Mov Disord* 2000; 15: 230-7.

Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson's Disease by posterior GPI pallidotomy: 1-year results of a pilot study. *Ann Neurol* 1996; 40: 355-66.

Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's Disease visualized by transcranial color-coded real-time sonography. *Neurology* 1995; 45: 182-4.

Bejjani BP, Dormont D, Pidoux B, et al. Bilateral subthalamic stimulation for Parkinson's Disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. *J Neurosurg* 2000; 92: 615-25.

Bejjani BP, Gervais D, Arnulf I, et al. Axial parkinsonian symptoms can be improved: The role of levodopa and bilateral subthalamic stimulation. *J Neurol Neurosurg Psychiatry* 2000; 68: 595-600.

- Bellomo G, Santambrogio L, Fiacconi M, et al. Plasma profiles of adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's Disease. *J Neurol* 1991; 238: 19-22.
- Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's Disease: Further results of randomised trial and confidential inquiry. *BMJ* 1998; 316: 1191-6.
- Berchou RC. Maximizing the benefit of pharmacotherapy in Parkinson's Disease. *Pharmacotherapy* 2000; 20: 33S-42S.
- Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomized, double-blind, placebo-controlled study. *Acta Neurol* 2000; 101: 372-80.
- Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's Disease. A multicenter 5-year study. *Eur Neurol* 1997; 37: 23-7.
- Bonucelli U, Picini P, Del Dotto P, et al. Apomorphine test for dopaminergic responsiveness: A dose assessment study. *Mov Disord* 1993; 8: 158-64.
- Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1997; 62: 133-40.
- Bromocriptine Multicentre Trial Group. Bromocriptine as initial therapy in elderly parkinsonian patients. *Age Aging* 1990; 19: 62-7.
- Bronstein JM, DeSalles A, DeLong MR. Stereotactic pallidotomy in the treatment of Parkinson's Disease: An expert opinion. *Arch Neurol* 1999; 56: 1064-9.
- Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's Disease, multiple system atrophy, and progressive supranuclear palsy. *Ann Neurol* 1990; 28: 547-55.
- Brooks DJ. PET and SPECT studies in Parkinson's Disease. *Baillieres Clin Neurol* 1997; 6: 69-87.
- Burchiel KJ, Anderson VC, Favre J, et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's Disease: Results of a randomized, blinded pilot study. *Neurosurgery* 1999; 45: 1375-82.
- Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's Disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. *J Neurol Neurosurg Psychiatry* 1994; 57: 278-84.
- Buttner T, Kuhn W, Muller T, et al. Distorted color discrimination in de novo parkinsonian patients. *Neurology* 1995; 45: 386-7.
- Buttner T, Kuhn W, Patzold T, et al. L-dopa improves color vision in Parkinson's Disease. *J Neural Transm* 1994; 7: 13-9.
- Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's Disease. *Ann Neurol* 1992; 32: S125-7.
- Calne DB, Teychenne PF, Leigh PHN, et al. Treatment of parkinsonism with bromocriptine. *Lancet* 1974; 2: 1355-6.
- Canter GJ, deLaTorre R, Mier M. A method for evaluating disability in patients with Parkinson's Disease. *J Nerv Ment Dis* 1961; 133: 143-7.
- Capildeo R. Implications of the 5-year CR FIRST trial. *Neurology* 1998; 50: S15-7.
- Caronti B, Tanda G, Colosimo C, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's Disease. *NeuroReport* 1999; 10: 2907-10.
- Clarke CE, Davies P. Systematic review of acute L-dopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 2000; 69: 590-4.
- Clarke CE, Speller JM. Lisuride for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
- Clarke CE, Speller JM. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.

Clarke CE, Speller JM. Pergolide for levodopa-induced complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.

Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.

Clarke CE, Zobkiw RM. Quality of life and care in Parkinson's Disease. *Brit J Clin Pract* 1995; 49: 288-93.

Comella CL, Stebbins GT, Brown-Toms N, et al. Physical therapy and Parkinson's Disease: A controlled clinical trial. *Neurology* 1994; 44: 376-8.

Dalvi A, Winfield L, Yu Q, et al. Stereotactic posteroventral pallidotomy: Clinical methods and results at 1-year follow up. *Mov Disord* 1999; 14: 256-61.

Dam M, Tonin P, Casson S, et al. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's Disease patients. *Adv Neurol* 1996; 69: 551-5.

D'Costa DF, Abbot RJ, Pye IF, et al. The apomorphine test in parkinsonian syndromes. *J Neurol Neurosurg Psychiatry* 1991; 10: 870-2.

de Bie RMA, de Haan RJ, Nijssen PCG, et al. Unilateral pallidotomy in Parkinson's Disease: A randomised, single-blind, multicentre trial. *Lancet* 1999; 354: 1665-9.

de Rijk MC, Breteler MMB, den Breeijen JH, et al. Dietary antioxidants and Parkinson Disease: The Rotterdam Study. *Arch Neurol* 1997; 54: 762-5.

de Rijk MC, Tzourio C, Breteler MMB, et al. Prevalence of parkinsonism and Parkinson's Disease in Europe: The EUROPARKINSON collaborative study. *J Neurol Neurosurg Psychiatry* 1997; 62: 10-5.

de Silva HAR, Khan NL, Wood NW. The genetics of Parkinson's Disease. *Curr Opin Genet Dev* 2000; 10: 292-8.

DeAngelis EC, Mourao LF, Ferraz HB, et al. Effect of voice rehabilitation on oral communication of Parkinson's Disease patients. *Acta Neurol Scand* 1997; 96: 199-205.

Defer GL, Widner H, Marie RM, et al. Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). *Mov Disord* 1999; 14: 572-84.

Delalande I, Destee A, Hache JC, et al. Visual evoked potentials and spatiotemporal contrast sensitivity changes in idiopathic Parkinson's Disease and multiple system atrophy. *Adv Neurol* 1996; 69: 319-25.

Desaloms JM, Krauss JK, Lai EC, et al. Posteroventral medial pallidotomy for treatment of Parkinson's Disease: Preoperative magnetic resonance imaging features and clinical outcome. *J Neurosurg* 1998; 89: 194-9.

Dewey RB, Giller CA, Broline SK, et al. Clinical outcome of unilateral stereotactic pallidotomy without microelectrode recording for intractable Parkinson's Disease. *Parkinsonism Relat* 2000; 6: 7-16.

Diederich N, Goetz CG, Stebbins GT, et al. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's Disease. *Neurology* 1992; 42: 1311-4.

Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's Disease. *Pharmacoeconomics* 1998; 14: 299-312.

Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's Disease. *Neurology* 1995; 45: 753-61.

Dogali M, Sterio D, Fazzini E, et al. Effects of posteroventral pallidotomy on Parkinson's Disease. *Adv Neurol* 1996; 69: 585-90.

Doty RL, Golbe LI, McKeown BA, et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's Disease. *Neurology* 1993; 43: 962-5.

Doty RL, Stern MB, Pfeiffer C, et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1992; 55: 138-42.

Duff J, Sime E. Surgical interventions in the treatment of Parkinson's Disease (PD) and Essential Tremor (ET): Medial pallidotomy in PD and chronic deep brain stimulation (DBS) in PD and ET. *Axone* 1997; 18: 85-9.

- Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. *Acta Neurol Scand* 1996; 93: 14-20.
- Eidelberg D, Moeller JR, Ishikawa T, et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's Disease. *Ann Neurol* 1996; 39: 450-9.
- Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's Disease with 18F-fluorodeoxyglucose and positron emission tomography. *Neurology* 1995; 45: 1995-2004.
- Eskandar EN, Shinobu LA, Penney JB, et al. Stereotactic pallidotomy performed without using microelectrode guidance in patients with Parkinson's Disease: Surgical technique and 2-year results. *J Neurosurg* 2000; 92: 375-83.
- Espino A, Calopa M, Ambrosio S, et al. CSF somatostatin increase in patients with early parkinsonian syndrome. *J Neural Transm* 1995; 9: 189-96.
- Factor SA, Brown D, Molho ES, et al. Clozapine: A two-year open trial in Parkinson's Disease patients with psychosis. *Neurology* 1994; 44: 544-6.
- Factor SA. Dopamine agonists. *Med Clin North Am*. 1999; 83: 415-43.
- Fahn S, Marsden CD, Calne DB, et al., eds. *Recent Developments in Parkinson's Disease*. vol 2. Florham Park, NJ. MacMillan Health Care Information 1987; pp 153-63, 293-304.
- Fahn S. Parkinson Disease, the effect of levodopa, and the ELLDOPA trial. *Arch Neurol* 1999; 56: 529-35.
- Fazzini E, Dogali M, Sterio D, et al. Stereotactic pallidotomy for Parkinson's Disease: A long term follow-up of unilateral pallidotomy. *Neurology* 1997; 48: 1273-7.
- Fehling C. Treatment of Parkinson's syndrome with L-dopa. A double blind study. *Acta Neurol Scand* 1966; 42: 367-72.
- Fields JA, Troster AI. Cognitive outcomes after deep brain stimulation for Parkinson's Disease: A review of initial studies and recommendations for future research. *Brain Cogn* 2000; 42: 268-93.
- Fine J, Duff J, Chen R, et al. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's Disease. *N Engl J Med* 2000; 342: 1708-14.
- Fink JS, Schumacher JM, Elias SL, et al. Porcine xenografts in Parkinson's Disease and Huntington's Disease patients: Preliminary results. *Cell Transplant* 2000; 9: 273-8.
- Formisano R, Pratesi L, Modarelli FT, et al. Rehabilitation and Parkinson's Disease. *Scand J Rehab Med* 1992; 24: 157-60.
- Fox MW, Ahlskog JE, Kelly PJ. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's Disease patients. *J Neurosurg* 1991; 75: 723-30.
- Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's Disease. *N Engl J Med* 2001; 344: 710-9.
- Freese A. Restorative gene therapy approaches to Parkinson's Disease. *Med Clin North Am* 1999; 83: 537-48.
- Fung VSC, Burne JA, Morris JGL. Objective quantification of resting and activated parkinsonian rigidity: A comparison of angular impulse and work scores. *Mov Disord* 2000; 15: 48-55.
- Gasser T, Schwarz J, Arnold G, et al. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's Disease. *Arch Neurol* 1992; 49: 1131-4.
- Gasser T. Is Parkinson's Disease an inherited condition? *Adv Neurol* 1999; 80: 143-52.
- Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. *Arch Neurol* 1999; 56: 33-9.
- Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1988; 51: 745-52.
- Gimenez-Roldan S, Tolosa E, Burguera JA, et al. Early combination of bromocriptine and levodopa in Parkinson's Disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. *Clin Neuropharmacol* 1997; 20: 67-76.

- Giobbe D, Castellano GC, Podio V. Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson's Disease. *Ital J Neurol Sci* 1993; 14: 165-9.
- Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. *Neurology* 2000; 54: 710-4.
- Goetz CG, Stebbins GE, Klawans HL, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. *Neurology* 1991; 41: 1719-22.
- Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's Disease: A quantitative and qualitative analysis. *J Neurol Neurosurg Psychiatry* 1986; 49: 381-9.
- Gross RE, Lombardi WJ, Lang AE, et al. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's Disease. *Brain* 1999; 122: 405-16.
- Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's Disease. *Neurology* 1997; 49: 1060-5.
- Hallett M, Litvan I. Evaluation of surgery for Parkinson's Disease: A report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 1999; 53: 1910-21.
- Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the parkin gene in affected individuals. *Ann Neurol* 1998; 44: 935-41.
- Hauser RA, Zesiewicz TA. Management of early Parkinson's Disease. *Med Clin North Am* 1999; 83: 393-414.
- Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1997; 62: 436-46.
- Hawkes CH, Shephard BC. Olfactory evoked responses and identification tests in
- Hedges LV. *The Handbook of Research Synthesis*. New York: Russell Sage Foundation; 1994. Chapter 19, Fixed Effects Models.
- Hellenbrand W, Boeving H, Robra BP, et al. Diet and Parkinson's Disease II: A possible role for past intake of specific nutrients. Results from a self administered food-frequency questionnaire in a case-control study. *Neurology* 1996; 47: 644-50.
- Hellenbrand W, Seidler A, Boeving H, et al. Diet and Parkinson's Disease I: A possible role for past intake of specific foods and food groups. Results from a self administered food-frequency questionnaire in a case-control study. *Neurology* 1996; 47: 636-42.
- Hellenbrand W, Seidler A, Robra BP, et al. Smoking and Parkinson's Disease: A case-control study in Germany. *Int J Epidemiol* 1997; 26: 328-39.
- Hely MA, Chey T, Wilson A, et al. Reliability of the Columbia scale for assessing signs of Parkinson's Disease. *Mov Disord* 1993; 8: 466-72.
- Hely MA, Morris JG, Reid WG, et al. The Sydney multicentre study of Parkinson's Disease: A randomised, prospective five-year study comparing low dose bromocriptine with low dose levodopa-carbidopa. *J Neurol Neurosurg Psychiatry* 1994; 57: 903-10.
- Hely MA, Morris JG, Reid WG, et al. Age at onset: The major determinant of outcome in Parkinson's Disease. *Acta Neurol Scand* 1995; 92: 455-63.
- Hely MA, Morris JG, Traficante R, et al. The Sydney multicentre study of Parkinson's Disease: Progression and mortality at 10 years. *J Neurol Neurosurg Psychiatry* 1999; 67: 300-7.
- Henderson BT, Clough CG, Hughes RC, et al. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's Disease. *Arch Neurol* 1991; 48: 822-7.
- Herrera EJ, Viano JC, Caceres M, et al. Posteroventral pallidotomy in Parkinson's Disease. *Acta Neurochir (Wien)* 2000; 142: 169-75.
- Hildick-Smith M. Pragmatic physical therapy in Parkinson's Disease: Any scientific basis? *Parkinson's Disease: Advances in Neurology* 1999; 80: 561-4.
- Hitchcock ER, Kenny BG, Clough CG, et al. Stereotactic implantation of foetal mesencephalon

- (STIM): The UK experience. *Prog Brain Res* 1990; 82: 723-8.
- Hoehn MM and Yahr MD. Parkinsonism: Onset, progression, and mortality. *Neurology* 1967; 17: 427-442.
- Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's Disease: A multicenter pilot study. *Magn Reson Med* 1995; 33: 589-94.
- Hornykiewicz O. Parkinson's Disease and its chemotherapy. *Biochem Pharmacol* 1975; 24: 1061-5.
- Horstink MW and Morrish PK. Preclinical diagnosis of Parkinson's Disease. *Parkinson's Disease: Advances in Neurology*. vol 80, 1999, Philadelphia: Lippincott Williams & Wilkins, pp. 327-33.
- Houeto JL, Damier P, Bejjani PB, et al. Subthalamic stimulation in Parkinson Disease: A multidisciplinary approach. *Arch Neurol* 2000; 57: 461-5.
- Hu CJ, Sung SM, Liu HS, et al. Polymorphisms of the parkin gene in sporadic Parkinson's Disease among Chinese in Taiwan. *Eur Neurol* 2000; 44: 90-3.
- Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's Disease: A clinicopathologic study. *Neurology* 1992; 42: 1142-6.
- Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's Disease. *Arch Neurol* 1993; 50: 140-8.
- Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. *Lancet* 1990; 336: 32-4.
- Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's Disease. *Neurology* 1991; 41: 1723-5.
- Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic
- Hutton JT, Morris JL, Elias JW. Visual contrast sensitivity in Parkinson's Disease is worsened with cabergoline treatment. *Parkinsonism Relat* 1999; 5: 87-91.
- Iacono RP, Shima F, Lonser RR, et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's Disease. *Neurosurgery* 1995; 36: 1118-27.
- Idanpaan-Heikkila J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with clozapine. *Eur J Clin Pharmacol* 1977; 11: 193-8.
- Imon Y, Matsuda H, Ogawa M, et al. SPECT image analysis using statistical parametric mapping in patients with Parkinson's Disease. *J Nucl Med* 1999; 40: 1583-9.
- Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's Disease patients with motor fluctuations. *Neurology* 1996; 47: 785-8.
- Irwig L, Tosteson ANA, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. *Ann Intern Med* 1994; 120: 667-76.
- Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Controlled Clinical Trials* 1996; 17: 1-12.
- Jahanshahi M, Brown RG, Whitehouse C, et al. Contact with a nurse practitioner: A short-term evaluation study in Parkinson's Disease and dystonia. *Behav Neurol* 1994; 7: 189-96.
- Jankovic J, Cardoso F, Grossman RG, et al. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. *Neurosurgery* 1995; 37: 680-7.
- Jankovic J, Hamilton WJ, Grossman RG. Thalamic surgery for movement disorders. *Adv Neurol* 1997; 74: 221-3.
- Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson Disease. *Arch Neurol* 2000; 57: 369-72.
- Jankovic J. New and emerging therapies for Parkinson Disease. *Arch Neurol* 1999; 56: 785-90.

Jimenez-Jimenez FJ, Rubio JC, Molina JA, et al. Cerebrospinal fluid carnitine levels in patients with Parkinson's Disease. *J Neurol Sci* 1997; 145: 183-5.

Johansson F, Malm J, Nordh E, et al. Usefulness of pallidotomy in advanced Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1997; 62: 125-32.

Johnson BT, Qun L, Castell JA, et al. Swallowing and esophageal function in Parkinson's Disease. *Amer J Gastroenterol* 1995; 90: 1741-6.

Johnson JA, Pring TR. Speech therapy and Parkinson's Disease: A review and further data. *Br J Disord Commun* 1990; 25: 183-94.

Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. *J Neurol* 1998; 245: 223-30.

Kaasinen V, Nagren K, Hietala J, et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's Disease. *Neurology* 2000; 54: 1482-7.

Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson's Disease. *Neurology* 1991; 41: 1699-700.

Katsikitis M, Pilowsky I. A controlled study of facial mobility treatment in Parkinson's Disease. *J Psychosom Res* 1996; 40: 387-96.

Katzen HL, Levin BE, Llabre ML. Age of disease onset influences cognition in Parkinson's Disease. *J Int Neuropsychol Soc* 1998; 4: 285-90.

Kishore A, Turnbull IM, Snow BJ, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's Disease. Six-month follow-up with additional 1-year observations. *Brain* 1997; 120: 729-37.

Kleedorfer B, Poewe W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's Disease. Preliminary findings in 20 patients. *J Neural Transm [P-D Sect]* 1992; 4: 173-8.

Koller WC, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. *Ann Neurol* 1997; 42: 292-9.

Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in

PD: A 5-year randomized multicenter study. *Neurology* 1999; 53: 1012-9.

Koller WC, Pahwa R, Lyons KE, et al. Surgical treatment of Parkinson's Disease. *J Neurol Sci* 1999; 167: 1-10.

Kondziolka D, Bonaroti E, Baser S, et al. Outcomes after stereotactically guided pallidotomy for advanced Parkinson's Disease. *J Neurosurg* 1999; 90: 197-202.

Kopyov OV, Jacques D, Lieberman A, et al. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson's Disease. *Cell Transplant* 1996; 5: 327-37.

Kopyov OV, Jacques DS, Lieberman A, et al. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue. *Exp Neurol* 1997; 146: 536-45.

Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's Disease: A 6-month interim report of a 3-year study. *Mov Disord* 1998; 13: 46-51.

Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's Disease. *Neurology* 1999; 53: 364-70.

Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's Disease. *Brain* 1998; 121: 451-7.

Kraft E, Schwarz J, Trenkwalder C, et al. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: A specific marker of multiple system atrophy? *Arch Neurol* 1999; 56: 225-8.

Krauss JK, Desaloms JM, Lai EC, et al. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's Disease: Postoperative magnetic resonance imaging analysis. *J Neurosurg* 1997; 87: 358-67.

Kulisevsky J, Garcia-Sanches C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's Disease. A two-year follow-up study of previously untreated patients. *Mov Disord* 2000; 15: 613-26.

- Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, et al. A six-month study of pergolide and levodopa in de novo Parkinson's Disease patients. *Clin Neuropharmacol* 1998; 21: 358-62.
- Kumar K, Kelly M, Toth C. Deep brain stimulation of the ventral intermediate nucleus of the thalamus for control of tremors in Parkinson's Disease and essential tremor. *Stereotact Funct Neurosurg* 1999; 72: 47-61.
- Kumar R, Lozano AM, Montgomery E, et al. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's Disease. *Mov Disord* 1998; 13: 73-82.
- Kunig G, Pogarell O, Moller JC, et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's Disease. *Clin Neuropharmacol* 1999; 22: 301-5.
- Lang AE, Lozano AM, Montgomery E, et al. Posteroventral medial pallidotomy in advanced Parkinson's Disease. *N Engl J Med* 1997; 337: 1036-42.
- Lang AE, Lozano AM. Parkinson's Disease: Second of two parts. *N Engl J Med* 1998; 339: 1130-43.
- Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantations. *Mov Disord* 1992; 7: 2-13.
- Larsen JP, Boas J, Erdal JE, et al. Does selegiline modify the progression of early Parkinson's Disease? Results from a five-year study. *Eur J Neurol* 1999; 6: 539-47.
- Larsen JP, Boas J. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian-Danish 5-year study. *Mov Disord* 1997; 12: 175-82.
- Latchman DS. Herpes simplex virus vectors for gene therapy in Parkinson's Disease and other diseases of the nervous system. *J R Soc Med* 1999; 92: 566-70.
- Lees AJ, Parkinson's Disease Research Group in the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's Disease. *BMJ* 1995; 311: 1602-7.
- Lehrner JP, Brucke T, Dal-Bianco P, et al. Olfactory functions in Parkinson's Disease and Alzheimer's Disease. *Chem Senses* 1997; 22: 105-10.
- Leroy E, Anastasopoulos D, Konitsiotis S, et al. Deletions in the parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's Disease. *Hum Genet* 1998; 103: 424-7.
- Liberini P, Parola S, Spano PF, et al. Olfaction in Parkinson's Disease: Methods of assessment and clinical relevance. *J Neurol* 2000; 247: 88-96.
- Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's Disease. *Neurology* 1998; 51: 1057-62.
- Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's Disease: Results of a double-blind, placebo-controlled, parallel-group study. *Neurology* 1997; 49: 162-8.
- Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. *J Clin Psychiatry* 1988; 49:271-7.
- Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's Disease. *N Engl J Med* 1998; 339: 1105-11.
- Limousin P, Speelman JD, Gielen F, et al. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. *J Neurol Neurosurg Psychiatry* 1999; 66: 289-96.
- Liss C, Bush D, Last B, et al. An interim report of a 5-year clinical study in patients with Parkinson's Disease with no prior levodopa therapy. *Clin Drug Invest* 1997; 13: 15-22.
- Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley & Sons; 1987.
- Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy Body Disease, Parkinson Disease, and dementia with Lewy bodies: A clinicopathologic study. *Arch Neurol* 1998; 55: 969-78.
- Logroscino G, Marder K, Cote T, et al. Dietary lipids and antioxidants in Parkinson's Disease: a population-based, case-control study. *Ann Neurol* 1996; 39: 89-94.

- Lopez-Lozano JJ, Abascal J, Bravo G. A year follow-up of autoimplants of perfused adrenal medulla into parkinsonian patients. *Prog Brain Res* 1990; 82: 657-63.
- Lopez-Lozano JJ, Bravo G, Abascal J, et al. Grafting of perfused adrenal medullary tissue into the caudate nucleus of patients with Parkinson's Disease. *J Neurosurg* 1991; 75: 234-43.
- Lopez-Lozano JJ, Bravo G, Abascal J. A long-term study of Parkinson's patients subjected to autoimplants of perfused adrenal medulla into the caudate nucleus. *Transplant Proc* 1990; 22: 2243-6.
- Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term follow-up in 10 Parkinson's Disease patients subjected to fetal brain grafting into a cavity in the caudate nucleus: The Clinica Puerta de Hierro experience. *Transplant Proc* 1995; 27: 1395-400.
- Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term improvement in patients with severe Parkinson's Disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. *J Neurosurg* 1997; 86: 931-42.
- Louis ED, Marder K, Cote L, et al. Mortality from Parkinson Disease. *Arch Neurol* 1997; 54: 260-4.
- Louis EK, Klatka LA, Liu Y, et al. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's Disease. *Neurology* 1997; 48: 376-80.
- Lozano AM, Lang AE, Galvez-Jiminez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's Disease. *Lancet* 1995; 346: 1383-7.
- Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's Disease and mutations in the parkin gene. *N Engl J Med* 2000; 342: 1560-7.
- MacMahon DG, Overstall PW, Marshall T. Simplification of the initiation of bromocriptine in elderly patients with advanced Parkinson's Disease. *Age Ageing* 1991; 20: 146-51.
- Magyar K, Haverle D. Neuroprotective and neuronal rescue effects of selegiline. *Neurobiology* 1999; 7: 175-90.
- Mally J, Stone TW. Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. *J Neurol Sci* 1999; 162: 179-84.
- Marsh L. Neuropsychiatric aspects of Parkinson's Disease. *Psychosomatics* 2000; 41: 15-23.
- Martignoni E, Pachetti C, Sibilla L, et al. Dihydroergocryptine in the treatment of Parkinson's Disease: A six months' double-blind clinical trial. *Clin Neuropharmacol* 1991; 14: 78-83.
- Martin WE, Loewenson RB, Resch JA, et al. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's Disease. *Neurology* 1974; 24: 912-9.
- Martinez-Martin P, Fontan C, Payo BF, et al. Parkinson's Disease: Quantification of disability based on the Unified Parkinson's Disease Rating Scale. *Neurologia* 2000; 15: 382-7.
- Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. *Mov Disord* 1994; 9: 76-83.
- Masterman D, DeSalles A, Baloh RW, et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson Disease. *Arch Neurol* 1998; 55: 1201-8.
- Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's Disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. *Am J Epidemiol* 1995; 142: 820-7.
- McManus DQ, Arvanitis LA, Kowalczyk BB, Seroquel Trial 48 Study Group. Seroquel (quetiapine), a novel antipsychotic: Experience in elderly patients with psychotic disorders. *J Clin Psychiatry* 1999; 60: 292-8.
- Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's Disease. *Age Ageing* 1999; 28: 99-102.
- Meco G, Alessandri A, Giustini P, et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's Disease: An open-label, long-term study. *Mov Disord* 1997; 12: 610-2.
- Melnick ME, Dowling GA, Aminoff MJ, et al. Effect of pallidotomy on postural control and motor

function in Parkinson Disease. *Arch Neurol* 1999; 56: 1361-5.

Mendis T, Suchowersky O, Lang A, et al. Management of Parkinson's Disease: A review of current and new therapies. *Can J Neurol Sci* 1999; 26: 89-103.

Mercer BS. A randomized study of the efficacy of the PROPATH program for patients with Parkinson's Disease. *Arch Neurol* 1996; 53: 881-4.

Meshulam RI, Moberg PJ, Mahr RN, et al. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's Diseases. *Arch Neurol* 1998; 55: 84-90.

Miller E, Berrios GE, Politynska B. The adverse effect of benzhexol on memory in Parkinson's Disease. *Acta Neurol Scand* 1987; 76: 278-82.

Mindham RHS. The place of dementia in Parkinson's Disease: A methodologic saga. *Parkinson's Disease: Advances in Neurology* 1999; 80: 403-8.

Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson Disease. *Arch Neurol* 2000; 57: 983-8.

Montastruc JL, Rascol O, Senard JM, et al. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's Disease: A five year follow up. *J Neurol Neurosurg Psychiatry* 1994; 57: 1034-8.

Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's Disease should begin with a dopamine agonist. *Mov Disord* 1999; 14: 725-30.

Montgomery EB, Baker KB, Lyons K, et al. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. *Neurology* 1999; 52: 757-62.

Montgomery EB, Koller WC, LaMantia TJK, et al. Early detection of probable idiopathic Parkinson's Disease: I. Development of a diagnostic test battery. *Mov Disord* 2000; 15: 467-73.

Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's Disease: A randomized controlled trial. *Am J Med* 1994; 97: 429-35.

Montgomery EB, Lyons K, Koller WD. Early detection of probable idiopathic Parkinson's Disease: II. A prospective application of a diagnostic test battery. *Mov Disord* 2000; 15: 474-8.

Morens DM, Grandinetti A, Davis JW, et al. Evidence against the operation of selective mortality in explaining association between cigarette smoking and reduced occurrence of idiopathic Parkinson Disease. *Am J Epidemiol* 1996; 144: 400-4.

Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1995; 59: 597-600.

Mulrow C, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. *Ann Intern Med* 1997; 126: 389-91.

Murofushi T, Mizuno M, Osanai R, et al. Olfactory dysfunction in Parkinson's Disease. *J Otorhinol Relat Spec* 1991; 53: 143-6.

Myllyla VV, Heinonen EH, Vuorinen JA, et al. Early selegiline therapy reduces levodopa dose requirement in Parkinson's Disease. *Acta Neurol Scand* 1995; 91: 177-82.

Myllyla VV, Sotaniemi KA, Hakulinen P, et al. Selegiline as the primary treatment of Parkinson's Disease: A long-term double-blind study. *Acta Neurol Scand* 1997; 95: 211-8.

Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. *Neurology* 1992; 42: 339-43.

Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as a primary treatment of Parkinson's Disease. *Acta Neurol Scand* 1991; 84: 70-2.

Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline in de novo parkinsonian patients: The Finnish study. *Mov Disord* 1993; 8: S41-4.

Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's Disease. *Scand J Rehab Med* 2000; 32: 11-5.

Nakanishi T, Iwata M, Goto I, et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. *Eur Neurol* 1992; 32: 9-22.

- Nakanishi T, Kanazawa I, Goto I, et al. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. *Eur Neurol* 1990; 30: 3-8.
- Nakanishi T, Kanazawa I, Iwata M, et al. Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: Analysis on the maintenance and the change of the original mode of treatment. *Eur Neurol* 1992; 32: 23-9.
- Nakanishi T, Mizuno Y, Goto I, et al. A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's Disease. The fourth interim report. *Eur Neurol* 1991; 31: 3-16.
- Nappi G, Martignoni E, Horowski R, et al. Lisuride plus selegiline in the treatment of early Parkinson's Disease. *Acta Neurol Scand* 1991; 83: 407-10.
- Olanow CW, Fahn S, Muentner M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's Disease. *Mov Disord* 1994; 9: 40-7.
- Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's Disease. *Ann Neurol* 1995; 38: 771-7.
- Olanow CW, Koller W, Goetz CG, et al. Autologous transplantation of adrenal medulla in Parkinson's Disease. 18-month results. *Arch Neurol* 1990; 47: 1286-9.
- Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. *Arch Neurol* 2000; 57: 263-7.
- Olsson JE. Bromocriptine and levodopa in early combination in Parkinson's Disease: First results of the collaborative European multicentric trial. *Adv Neurol* 1990; 53: 421-3.
- Otsuka M, Ichiya Y, Hosokawa S, et al. Striatal blood flow, glucose metabolism and 18F-Dopa uptake: Difference in Parkinson's Disease and atypical parkinsonism. *J Neurol Neurosurg Psychiatry* 1991; 54: 898-904.
- Pacchetti C, Aglieri R, Mancini F, et al. Active music therapy and Parkinson's Disease: Methods. *Funct Neurol* 1998; 13: 57-67.
- Pacchetti C, Mancini F, Aglieri R, et al. Active music therapy in Parkinson's Disease: An integrative method for motor and emotional rehabilitation. *Psychosom Med* 2000; 62: 386-93.
- Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. *Neurology* 1998; 51: 520-5.
- Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's Disease: Design and methods of the CALM-PD study. *Clin Neuropharmacol* 2000; 23: 34-44.
- Parkinson Study Group. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's Disease. *Eur Neurol* 1992; 32: 46-53.
- Parkinson Study Group. Effect of selegiline (Deprenyl) on the progression of disability in early Parkinson's Disease. *Acta Neurol Scand Suppl* 1993; 87: 36-42.
- Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's Disease. *Arch Neurol* 1995; 52: 565-70.
- Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's Disease in DATATOP patients not requiring levodopa. *Ann Neurol* 1996; 39: 29-36.
- Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's Disease in DATATOP patients requiring levodopa. *Ann Neurol* 1996; 39: 37-45.
- Parkinson Study Group. Mortality in DATATOP: A multicenter trial in early Parkinson's Disease. *Ann Neurol* 1998; 43: 318-25.
- Parkinson Study Group. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's Disease. *Neurology* 1994; 44: 1756-9.
- Parkinson Study Group. The need for levodopa as an end point of Parkinson's Disease progression in a clinical trial of selegiline and alpha-tocopherol. *Mov Disord* 1997; 12: 183-9.
- Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's Disease. *Ann Neurol* 1996; 40: 99-107.

Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's Disease. *N Engl J Med* 1993; 328: 176-83.

Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's Disease patients. *Ann Neurol* 1997; 42: 747-55.

Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's Disease: A randomized controlled trial. *JAMA* 2000; 284: 1931-8.

Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's Disease: Three year interim report. *BMJ* 1993; 307: 469-72.

Parkinson's disease: a clinicopathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992; 55: 1142-6.

Patti F, Reggio A, Nicoletti F, et al. Effects of rehabilitation therapy on parkinsonians' disability and functional independence. *J Neuro Rehab* 1996; 10: 223-31.

Perrine K, Dogali M, Fazzini E, et al.. Cognitive functioning after pallidotomy for refractory Parkinson's Disease. *J Neurol Neurosurg Psychiatry* 1998; 65: 150-4.

Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's Disease: Evidence from a longitudinal study of dopaminergic function in twins. *Ann Neurol* 1999; 45: 577-82.

Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson's Disease. *Arch Neurol* 1987; 44: 270-2.

Pizzolato G, Cagnin A, Rossato A, et al. Striatal dopamine D2 receptor alterations and response to L-dopa in Parkinson's Disease. *Adv Neurol* 1996; 69: 467-73.

Platz T, Brown RG, Marsden CD. Training improves the speed of aimed movements in Parkinson's Disease. *Brain* 1998; 121: 505-14.

Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's Disease to chromosome 4q21-q23. *Science* 1996; 274: 1197-8.

Potagas C, Dellatolas G, Ziegler M, et al. Clinical assessment of olfactory dysfunction in Parkinson's Disease. *Mov Disord* 1998; 13: 394-9.

Prasad KN, Cole WC, Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's Disease. *J Am Coll Nutr* 1999; 18: 413-23.

Przuntek H, Conrad B, Dichgans J, et al. SELEDO: A 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. *Eur J Neurol* 1999; 6: 141-50.

Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: PRADO-study discontinued. *Eur J Clin Pharmacol* 1992; 43: 357-63.

Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's Disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. *J Neural Transm Park Dis Dement Sect* 1996; 103: 699-715.

Przuntek H, Welzel D, Schwarzmans D, et al. Primary combination therapy of early Parkinson's Disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report. *Eur Neurol* 1992; 32: 36-45.

Rabey JM, Streifler M, Treves T, et al. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's Disease. *Adv Neurol* 1990; 53: 451-5.

Rabey JM, Treves TA, Neufeld MY. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's Disease. *Neurology* 1995; 45: 432-4.

Racette BA, McGee-Minnich L, Moerlein SM, et al. Welding-related parkinsonism. Clinical features, treatment, and pathophysiology. *Neurology* 2001; 56: 8-13.

Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. *Neurology* 1997; 49: 1066-71.

- Rajput AH, Rodzilsky B, Rajput A. Accuracy of clinical diagnosis of Parkinsonism - a prospective study. *Can J Neurol Sci* 1991; 18: 275-8.
- Rajput AH, Rozdilsky B, Ang L. Occurrence of resting tremor in Parkinson's Disease. *Neurology* 1991; 41: 1298-9.
- Rajput AH, Rozdilsky B, Rajput A, et al. Levodopa efficacy and pathological basis of Parkinson syndrome. *Clin Neuropharmacol* 1990; 13: 553-8.
- Ramaker C, Johan WT, van de Beek, MS. The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review. *Mov Disord* 2000; 15: 56-64.
- Ramig LO, Countryman S, O'Brien C, et al. Intensive speech treatment for patients with Parkinson's Disease: Short- and long-term comparison of two techniques. *Neurology* 1996; 47: 1496-504.
- Ramig LO, Countryman S, Thompson LL, et al. Comparison of two forms of intensive speech treatment for Parkinson's Disease. *J Speech Hear Res* 1995; 38: 1232-51.
- Ramig LO, Sapir S, Fox C, et al. Changes in vocal loudness following intensive voice treatment in individuals with Parkinson's Disease: A comparison with untreated patients and normal age-matched controls. *Mov Disord* 2001; 16: 79-83.
- Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's Disease: A 6-month interim report of a 5-year levodopa-controlled study. *Mov Disord* 1998; 13: 39-45.
- Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's Disease who were treated with ropinirole or levodopa. *N Engl J Med* 2000; 342: 1484-91.
- Raudenbush SW. *The Handbook of Research Synthesis*. New York: Russell Sage Foundation; 1994. Chapter 20, Random Effects Models.
- Razmy A, Shapiro CM. Interactions of sleep and Parkinson's Disease. *Semin Clin Neuropsychiatry* 2000; 5: 20-32.
- Reid WGJ, Hely MA, Morris JGL, et al. A longitudinal study of Parkinson's Disease: Clinical and neuropsychological correlates of dementia. *J Clin Neurosci* 1996; 3: 327-33.
- Relja MA, Petravic D, Kolaj M. Quantifying rigidity with a new computerized elbow device. *Clin Neuropharmacol* 1996; 19: 148-56.
- Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's Disease nurse specialist. *Int J Nurs Stud* 2000; 37: 337-49.
- Riess O, Jakes R, Kruger R. Genetic dissection of familial Parkinson's Disease. *Mol Med Today* 1998; 4: 438-44.
- Rinne JO, Laihin A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's Disease: A PET study with [¹¹C] raclopride. *J Neurol Sci* 1995; 132: 156-61.
- Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson's Disease: [¹⁸F]fluorodopa positron emission tomographic study. *Arch Neurol* 2000; 57: 470-5.
- Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's Disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. *Neurology* 1997; 48: 363-8.
- Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's Disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. *Drugs* 1998; 55: 23-30.
- Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. *Neurology* 1998; 51: 1309-14.
- Roberts-Warrior D, Overby A, Jankovic J, et al. Postural control in Parkinson's Disease after unilateral posteroventral pallidotomy. *Brain* 2000; 123: 2141-9.
- Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson's Disease. *JAMA* 2000; 283: 2674-9.
- Ruggieri S, DePandis MF, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's Disease. *Clin Neuropharmacol* 1997; 20: 204-9.

- Ryvlin P, Broussole E, Piollet H, et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's Disease. *Arch Neurol* 1995; 52: 583-8.
- Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. *N Engl J Med* 1987; 316: 450-5.
- Sakuma K, Nakashima K, Takahashi K. Olfactory evoked potentials in Parkinson's Disease, Alzheimer's disease, and anosmic patients. *Psychiatry Clin Neurosci* 1996; 50: 35-40.
- Samii A, Turnbull IM, Kishore A, et al. Reassessment of unilateral pallidotomy in Parkinson's Disease. A 2-year follow-up study. *Brain* 1999; 122: 417-25.
- Samuel M, Caputo E, Brooks DJ, et al. A study of medial pallidotomy for Parkinson's Disease: Clinical outcome, MRI location and complications. *Brain* 1998; 121: 59-75.
- Sano M, Stern Y, Marder K, et al. A controlled trial of piracetam in intellectually impaired patients with Parkinson's Disease. *Mov Disord* 1990; 5: 230-4.
- Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinson's Disease from normality. Discriminant function analysis of fludopa F 18 positron emission tomography data. *Arch Neurol* 1994; 51: 237-43.
- Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinson's Disease and its pharmacologic treatment on quality of life and economic outcomes. *Am J Health-Syst Pharm* 2000; 57: 953-62.
- Schelosky L, Hierholzer J, Wissel J, et al. Correlation of clinical response in apomorphine test with D2 receptor status as demonstrated by 123I IBZM-SPECT. *Mov Disord* 1993; 8: 453-8.
- Schenckman M, Cutson TM, Kuchibhatla M, et al. Exercise to improve spinal flexibility and function for people with Parkinson's Disease: A randomized, controlled trial. *J Am Geriatr Soc* 1998; 46: 1207-16.
- Schmand B, de Bie RM, Koning-Haanstra M, de Smet JS, Speelman JD, van Zomeren AH. Unilateral pallidotomy in PD: A controlled study of cognitive and behavioral effects. *Neurology* 2000; 54: 1058-64.
- Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's Disease. *Brain* 2000; 123: 2297-305.
- Schulz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's Disease: A review of the literature. *J Commun Disord* 2000; 33: 59-88.
- Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *N Engl J Med* 2000; 342: 461-8.
- Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's Disease. In Gillingham FJ, Donaldson IML, eds. *Third Symposium of Parkinson's Disease*. Edinburgh, Scotland: E&S Livingstone; 1969. p 152-7.
- Schwarz J, Antonini A, Tatsch K, et al. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. *Nucl Med Commun* 1994; 15: 806-13.
- Schwarz J, Kraft E, Vogl T, et al. Relative quantification of signal on T2-weighted images in the basal ganglia: Limited value in differential diagnosis of patients with parkinsonism. *Neuroradiology* 1999; 41: 124-7.
- Schwarz J, Linke R, Kerner M, et al. Striatal dopamine transporter binding assessed by [I-123_IPT and single photon emission computed tomography in patients with early Parkinson' Disease: Implications for a preclinical diagnosis. *Arch Neurol* 2000; 57: 205-8.
- Schwarz J, Tatsch K, Arnold G, et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. *Neurology* 1993; 43: S17-20.
- Schwarz J, Tatsch K, Arnold G, et al. 123 I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with 'de novo' parkinsonism. *Neurology* 1992; 42: 556-61.
- Schwarz J, Tatsch K, Gasser T, et al. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. *Mov Disord* 1997; 12: 898-902.
- Schwarz J, Tatsch K, Gasser T, et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. *Mov Disord* 1998; 13: 16-9.
- Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic

[123I] -CIT striatal uptake correlates with symptom severity in Parkinson's Disease. *Ann Neurol* 1995; 38: 589-98.

Selby G. Stereotactic surgery for the relief of Parkinson's Disease. *J Neurol Sci* 1967; 5: 343-75.

Semchuk KK, Love EJ, Lee RG. Parkinson's Disease and exposure to agricultural work and pesticide chemicals. *Neurology* 1992; 42: 1328-35.

Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson Disease: A 12-month experience. *Arch Neurol* 1998; 55: 1211-6.

Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's Disease. *Neurology* 1997; 49: 724-8.

Shannon KM, Penn RD, Kroin JS, et al. Stereotactic pallidotomy for the treatment of Parkinson's Disease. Efficacy and adverse effects at 6 months in 26 patients. *Neurology* 1998; 50: 434-8.

Shoulson I and Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). *Acta Neurol Scand* 1989; 126: 171-5.

Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's Disease. *Biofactors* 1999; 9: 267-72.

Simon DK, Standaert DG. Parkinson's Disease and parkinsonian syndromes: Neuroprotective therapies. *Med Clin North Am* 1999; 83: 509-23.

Sitzia J, Haddrell V, Rice-Oxley M. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. *Clin Rehabil* 1998; 12: 389-94.

Smith ME, Ramig LO, Dromey C, et al. Intensive voice treatment in Parkinson's Disease: Laryngostroboscopic findings. *J Voice* 1995; 9: 453-9.

Snow BJ, Macdonald L, Mcauley D, et al. The effect of amantadine of levodopa-induced dyskinesias in Parkinson's Disease: A double-blind, placebo-controlled study. *Clin Neuropharmacol* 2000; 23: 82-5.

Stacy M, Jankovic J. Differential diagnosis of Parkinson's Disease and the Parkinsonism plus syndromes. *Neurol Clin* 1992; 10: 341-59.

Stacy M. Managing late complications of Parkinson's Disease. *Med Clin North Am* 1999; 83: 469-81.

Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. *CMAJ* 1998: 158.

Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. *J Neurol* 1996; 243: 68-72.

Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative chronic study. *Adv Neurol* 1993; 60: 653-5.

Stoof JC, Winogrodzka A, van Muiswinkel FL, et al. Leads for the development of neuroprotective treatment in Parkinson's Disease and brain imaging methods for estimating treatment efficacy. *Eur J Pharmacol* 1999; 375: 75-86.

Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson's Disease. *Br J Radiol* 1991; 64: 890-3.

Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's Disease in Iceland. *N Engl J Med* 2000; 343: 1767-70.

Taha JM, Favre J, Baumann TK, et al. Tremor control after pallidotomy in patients with Parkinson's Disease: Correlation with microrecording findings. *J Neurosurg* 1997; 86: 642-7.

Tanner CM, Golman SM. Epidemiology of Parkinson's Disease. *Neurol Clin* 1996; 14: 317-35.

Tanner CM, Ottman R, Golman SM, et al. Parkinson Disease in twins: an etiologic study. *JAMA* 1999; 281: 341-6.

Targum SD, Abbott JL. Efficacy of quetiapine in parkinson's patients with psychosis. *J Clin Psychopharmacol* 2000; 20: 54-60.

Tatsch K, Schwarz J, Oertel WH, et al. SPECT imaging of dopamine D2 receptors with 123I-IBZM: Initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. *Nucl Med Commun* 1991; 12: 699-707.

- Tatton WG, Wadia JS, Ju WY, et al. Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. *J Neural Transm* 1996; 48: 45-59.
- Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's Disease patients. *Mov Disord* 1996; 11: 193-200.
- Trepanier LL, Saint-Cyr JA, Lozano AM, Lang AE. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's Disease. *Neurology* 1998; 51: 207-15.
- Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's Disease: A retrospective analysis of a large multicentered clinical experience. *Mov Disord* 1998; 13: 377-82.
- Tzourio C, Rocca WA, Breteler MMB, et al. Smoking and Parkinson's Disease: An age-dependent risk effect? *Neurology* 1997; 49: 1267-72.
- Uitti RJ. Surgical treatments for Parkinson's Disease. *Can Fam Phys* 2000; 46: 368-73.
- van Hilten JJ, Ramaker C, van de Beek WJT, et al. Bromocriptine for levodopa-induced motor complications in Parkinson's Disease (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2000. Oxford: Update Software.
- Velasco F, Velasco M, Rodriguez Cuevas H, et al. Autologous adrenal medullary transplants in advanced Parkinson's Disease with particular attention to the selective improvement in symptoms. *Stereotact Funct Neurosurg* 1991; 57: 195-212.
- Veldman BA, Wijn AM, Knoers N, et al. Genetic and environmental risk factors in Parkinson's Disease. *Clin Neurol Neurosurg* 1998; 100: 15-26.
- Vitek JL, Bakay RA, DeLong MR. Microelectrode-guided pallidotomy for medically intractable Parkinson's Disease. *Adv Neurol* 1997; 74: 183-98.
- Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinson's Disease: Chart review of 49 patients. *J Neuropsychiatry Clin Neurosci* 1996; 8: 276-80.
- Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's Disease. *Adv Neurol* 1990; 53: 245-9.
- Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's Disease: Efficacy and safety of long-term treatment. *Neurology* 1997; 49: 665-71.
- Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's Disease. *Neurology* 1993; 43: 21-7.
- Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. *Mov Disord* 1999; 14: 947-50.
- Wermuth L, Sorensen PS, Timm B, et al. Depression in idiopathic Parkinson's Disease treated with citalopram. *Nord J Psychiatry* 1998; 52:163-9.
- Williams AC, Smith ML, Waring RH, et al. Idiopathic Parkinson's Disease: A genetic and environmental model. *Adv Neurol* 1999; 80: 215-8.
- Wolters EC, Horstink MW, Roos RA, et al. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's Disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. *Clin Neurol Neurosurg* 1992; 94: 205-11.
- Wolters EC, Horstink MW, Roos RA, et al. Superior clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's Disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. *Adv Neurol* 1993; 60: 648-52.
- Wolters EC, Tesselaaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's Disease. *J Neurol* 1996; 243: 235-40.
- Wszolek ZK, Markopoulou K. Olfactory dysfunction in Parkinson's Disease. *Clin Neurosci*. 1998; 5: 94-101.
- Young RF, Shumway-Cook A, Vermeulen SS, et al. Gamma knife radiosurgery as a lesioning technique in movement disorder surgery. *J Neurosurg* 1998; 89: 183-93.
- Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's Disease: An updated review. *Neuroepidemiology* 1993; 12: 195-208.